Cytogen's ProstaScint enters IMRT (intensity modulated radiation therapy) trials:
This article was originally published in Clinica
Executive Summary
A phase I/II clinical study is underway to evaluate Cytogen's ProstaScint imaging agent in improving the precision of intensity modulated radiation therapy (IMRT) for prostate cancer. ProstaScint, a radiolabelled monoclonal antibody, is injected intravenously into the patient where it binds to a highly expressed marker for prostate cancer. The enhanced images will allow for radiation to be more highly focused on the tumour, reducing damage to the surrounding tissue, said the Princeton, New Jersey firm.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.